Land: Storbritannia
Språk: engelsk
Kilde: VMD (Veterinary Medicines Directorate)
Meloxicam
Ecuphar NV
QM01AC06
Meloxicam
Expired
Revised: November 2015 AN: 01432/2014 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Acticam 2.5mg Chewable Tablets for Dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each chewable tablet contains: ACTIVE SUBSTANCE: Meloxicam 2.5 mg EXCIPIENTS: For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Chewable tablets Light lemon yellow, honey flavoured, round, biconvex, uncoated tablet, debossed with 'M2' on either side of breakline on one side and plain on other side. The tablet can be divided into two equal parts. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Alleviation of inflammation and pain in both acute and chronic musculo- skeletal disorders. 4.3 CONTRAINDICATIONS Do not use in pregnant or lactating animals. Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. Do not use in dogs less than 6 weeks of age or less than 10 kg body weight. Do not use in case of hypersensitivity to the active substance or to any of the excipients. Page 1 of 6 Revised: November 2015 AN: 01432/2014 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought. Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity. This product for dogs should not be used in cats as it is not suitable for use in this species. SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT TO ANIMALS People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. 4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNES Les hele dokumentet